These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19822712)

  • 1. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.
    de Vries MK; Brouwer E; van der Horst-Bruinsma IE; Spoorenberg A; van Denderen JC; Jamnitski A; Nurmohamed MT; Dijkmans BA; Aarden LA; Wolbink GJ
    Ann Rheum Dis; 2009 Nov; 68(11):1787-8. PubMed ID: 19822712
    [No Abstract]   [Full Text] [Related]  

  • 2. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
    de Vries MK; Wolbink GJ; Stapel SO; de Groot ER; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
    Ann Rheum Dis; 2007 Jan; 66(1):133-4. PubMed ID: 17178760
    [No Abstract]   [Full Text] [Related]  

  • 3. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
    de Vries MK; Wolbink GJ; Stapel SO; de Vrieze H; van Denderen JC; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
    Ann Rheum Dis; 2007 Sep; 66(9):1252-4. PubMed ID: 17472991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
    Arends S; Lebbink HR; Spoorenberg A; Bungener LB; Roozendaal C; van der Veer E; Houtman PM; Griep EN; Limburg PC; Kallenberg CG; Wolbink GJ; Brouwer E
    Clin Exp Rheumatol; 2010; 28(5):661-8. PubMed ID: 20822711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment.
    Bartelds GM; Wolbink GJ; Stapel S; Aarden L; Lems WF; Dijkmans BA; Nurmohamed MT
    Ann Rheum Dis; 2006 Sep; 65(9):1249-50. PubMed ID: 16905585
    [No Abstract]   [Full Text] [Related]  

  • 6. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
    Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
    Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.
    Haibel H; Rudwaleit M; Brandt HC; Grozdanovic Z; Listing J; Kupper H; Braun J; Sieper J
    Arthritis Rheum; 2006 Feb; 54(2):678-81. PubMed ID: 16447247
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous leishmaniasis in a patient with ankylosing spondylitis using adalimumab.
    Gomes KW; Benevides AN; Vieira FJ; Burlamaqui MP; Vieira Mde A; Fontenelle LM
    Rev Bras Reumatol; 2012; 52(3):447-52. PubMed ID: 22641598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.
    Henderson C; Davis JC
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):211-8. PubMed ID: 16932687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiopulmonary arrest after severe anaphylactic reaction to second infusion of infliximab in a patient with ankylosing spondylitis.
    Miki H; Okamoto A; Ishigaki K; Sasaki O; Sumitomo S; Fujio K; Yamamoto K
    J Rheumatol; 2011 Jun; 38(6):1220. PubMed ID: 21632692
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.
    Song IH; Maksymowych WP
    Rheum Dis Clin North Am; 2012 Aug; 38(3):613-33. PubMed ID: 23083759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
    Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
    J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Occurrence of vitiligo in a patient with ankylosing spondylitis receiving adalimumab].
    Toussirot E; Salard D; Algros MP; Aubin F
    Ann Dermatol Venereol; 2013 Dec; 140(12):801-2. PubMed ID: 24315228
    [No Abstract]   [Full Text] [Related]  

  • 16. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
    Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C
    Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842
    [No Abstract]   [Full Text] [Related]  

  • 17. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
    Gaspersic N; Sersa I; Jevtic V; Tomsic M; Praprotnik S
    Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ankylosing spondylarthritis--what is new in diagnosis and therapy?].
    Kathmann W
    Dtsch Med Wochenschr; 2006 Oct; Suppl 1():51-2. PubMed ID: 17595822
    [No Abstract]   [Full Text] [Related]  

  • 20. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
    Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
    Ann Rheum Dis; 2013 Jul; 72(7):1265-7. PubMed ID: 23482472
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.